CoChat

Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret

Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., Di Marzo, V. · 2007 · European Journal of Neuroscience
Cited by 120

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Cannabinoid (CB) agonists suppress nausea and vomiting (emesis). Similarly, transient receptor potential vanilloid‐1 (TRPV1) receptor agonists are anti‐emetic. Arvanil, N‐(3‐methoxy‐4‐hydroxy‐benzyl)‐arachidonamide, is a synthetic ‘hybrid’ agonist of CB 1 and TRPV1 receptors. Anandamide and N‐arachidonoyl‐dopamine (NADA) are endogenous agonists at both these receptors. We investigated if arvanil, NADA and anandamide were anti‐emetic in the ferret and their mechanism of action. All compounds reduced the episodes of emesis in response to morphine 6 glucuronide. These effects were attenuated by AM251, a CB 1 antagonist that was pro‐emetic per se, and TRPV1 antagonists iodoresiniferatoxin and AMG 9810, which were without pro‐emetic effects. Similar sensitivity to arvanil and NADA was found for prodromal signs of emesis. We analysed the distribution of TRPV1 receptors in the ferret brainstem and, for comparison, the co‐localization of CB 1 and TRPV1 receptors in the mouse brainstem. TRPV1 immunoreactivity was largely restricted to the nucleus of the solitary tract of the ferret, with faint labeling in the dorsal motor nucleus of the vagus and sparse distribution in the area postrema. A similar distribution of TRPV1, and its extensive co‐localization with CB 1, was observed in the mouse. Our findings suggest that CB 1 and TRPV1 receptors in the brainstem play a major role in the control of emesis by agonists of these two receptors. While there appears to be an endogenous ‘tone’ of CB 1 receptors inhibiting emesis, this does not seem to be the case for TRPV1 receptors, indicating that endogenously released endocannabinoids/endovanilloids inhibit emesis preferentially via CB 1 receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1460-9568.2007.05521.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 120

Metadata

Authors
Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., & Di Marzo, V.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2007-05
Volume
25
Issue
9
Pages
2773-2782
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W1824181778
Cited by
120
References
6
FWCI
8.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. https://app.cochat.ai/papers/10.1111/j.1460-9568.2007.05521.x
The paper
Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., & Di Marzo, V. (2007). Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2007.05521.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.